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Abstract
Introduction: Human prion diseases are a group of rare en-
cephalopathies resulting in rapidly progressive dementia and
ultimately death. While there are no effective treatments for
any form of prion disease, prompt and efficient diagnosis is
essential to prevent the spread of the self-propagating pro-
tein, which may occur through aerosols, and avoid unneces-
sary or invasive testing. Diagnosis relies largely on physical
examination, with many nonspecific findings, and laboratory
testing, which has wide ranges of reported accuracy and high
false positive rates with diseases such as Alzheimer’s demen-
tia.
Methods: Patients who underwent testing for prion dis-
ease were retrospectively identified from the electronic health
records at a single-center university hospital. Presenting
symptoms, as well as laboratory, radiographic, and electroen-
cephalogram findings, were recorded and analyzed by group
of final diagnosis, including prion disease, not prion disease,
and undiagnosed.
Results: There were 27 patients identified, two who had a fi-
nal diagnosis of prion disease, 20 who had a formal diagnosis
other than prion disease, and five who remained undiagnosed
until death. There was a high degree of overlap in present-
ing symptoms. A high rate of false positive laboratory values,
higher than previously reported, occurred for both the protein
14-3-3 and total Tau in cerebrospinal fluid. Magnetic reso-
nance imaging ruled out prion disease most often. Testing
with Rt-QuIC was the most diagnostic laboratory test. Both
patients with a diagnosis of prion disease developed pneumo-
nia and died of respiratory failure, and a total of nine patients
required intubation for respiratory infections.
Conclusion: Diagnosing prion disease remains a challenge
due to nonspecific physical exam findings and symptoms and
the high false positive rates of the laboratory algorithm. Test-
ing with Rt-QuIC should be performed in patients that are crit-
ically ill or may have diseases known to cause high false pos-
itive rates of 14-3-3 or total Tau. Proper personal protective
equipment should be used for any aerosol-generating proce-
dure in patients who may have prion disease.
ULJRI | https://ir.library.louisville.edu/jri/vol5/iss1/29 1
ULJRI Prion Disease: A Challening Diagnosis
Introduction
Human prion disease is a group of rare, spongiform en-
cephalopathies caused by alteration of a naturally oc-
curring protein resulting in rapidly progressive demen-
tia, neurologic symptoms, and ultimately death.[1-4]
Prion disease in humans is a transmissible spongiform
encephalopathy known as Creutzfeldt-Jakob Disease
(CJD) and can be broken down into sporadic (sCJD),
familial, acquired (including iatrogenic), and variant
(vCJD).[2, 5] Of all subgroups, sporadic CJD (sCJD)
comprises roughly 85% of cases and is the most widely
studied.[2]
While there are no effective treatments for any form
of CJD, prompt diagnosis is essential to prepare both
the patient and family for the inevitable outcomes,
to prevent unnecessary testing, and to prevent iatro-
genic spread of the self-propagating, aberrant prion
protein.[6-9] While most commonly spread through di-
rect contact with instrumentation contaminated with
central nervous system (CNS) contents, it has been
demonstrated that aerosolized prion protein can in-
fect mice with high efficiency.[10] The spread of CJD
is rare but deadly, and the safest and most unambigu-
ous cleaning of surgical equipment requires incinera-
tion.[8] To ensure proper decontamination and safety
precautions, a difficult diagnosis must first be made.
To definitively diagnose sCJD, a brain biopsy must
show aberrantly folded prion protein (PRPsc).[11] Since
a brain biopsy is strictly diagnostic and has no bearing
on treatment, a number of clinical criteria have been
developed to classify probable and possible prion disease
that largely rely on physical examination.[11, 12]
Physicians must have knowledge of the presentation
and diagnosis of prion disease to properly treat pa-
tients, decontaminate instruments properly, and pre-
vent the spread of CJD. We retrospectively identified
patients at a single center who underwent testing for
prion disease. We sought to identify and character-
ize the incidence of specific presenting symptoms and
physical exam findings and investigate the efficacy of
the laboratory testing algorithm used at our institution.
Methods
This study was approved by the University of
Louisville Institutional Review Board (IRB number
17.1323), and informed consent was waived as this was
a retrospective study.
Patient population
Patients were identified using electronic health records
at the University of Louisville Hospital between 2014
and 2019. Patients were included if they had a CSF
sample analyzed for markers of prion disease. Elec-
tronic health records of readmissions were also re-
viewed, and local obituaries were searched for deaths
after admission.
Study definitions
Diagnostic group was determined per the Centers for
Disease Control and Prevention (CDC) guidelines for
diagnosis of sCJD and vCJD, presented in Figure 1.[13,
14] Patients without a diagnosis, CJD or otherwise, at
the time of death were separated into the undiagnosed
group.
MRI criteria
Positive criteria by magnetic resonance imaging (MRI)
were defined by Fragoso et al. and the CDC.[2, 13, 14]
These results were further separated into typical find-
ings, corresponding to the most commonly identified
MRI signs in sCJD, and atypical findings, corresponding
with findings indicative of vCJD or the sCJD variants.
EEG criteria
Positive electroencephalogram (EEG) criteria were de-
fined as the presence of periodic sharp wave com-
plexes.
Data collection
Data were collected on 9 cognitive symptoms, 4 cere-
bellar symptoms, 10 behavioral symptoms, 7 general
symptoms, 8 motor symptoms, 3 sensory symptoms,
3 visual symptoms, and seizure tendencies. Study
data were collected and managed using REDCap elec-
tronic data capture tools hosted at the University of
Louisville.[15, 16] According to the company, “RED-
Cap (Research Electronic Data Capture) is a secure,
web-based software platform designed to support data
capture for research studies, providing 1) an intuitive
interface for validated data capture; 2) audit trails for
tracking data manipulation and export procedures; 3)
automated export procedures for seamless data down-
loads to common statistical packages; and 4) proce-
dures for data integration and interoperability with ex-
ternal sources.”
Data analysis
Data were analyzed using Stata/IC 16.1 (StataCorp
LLC, College Station, TX).[17] Categorical variables
were reported as frequency and percentage whereas
continuous variables were described as mean, range,
and standard deviation (SD). Sensitivity and specificity
of lab testing were calculated with standard equations.
The patients were classified based on the final diagno-
sis and separated into 5 groups: definite prion disease,
probable prion disease, possible prion disease, non-CJD, and
undiagnosed. Summary statistics of clinical data were
presented for each group.
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2. Exclusion of other likely
diagnoses
3. Disease duration <2
years
Brain biopsy with PRPsc
Two or more of
1. Myoclonus




One or more of
1. PSWCs on EEG
2. Positive 14-3-3
3. Positive MRI
Figure 1. Diagnostic criteria for CJD, adapted from the CDC.
Abbreviations: PSCW, periodic sharp wave complexes; EEG, electroencephalogram, PRPsc, prion protein scrapie isoform.
Results
The study included 27 patients, 13 males and 14 fe-
males. There was one patient with biopsy-confirmed
prion disease and one patient who met criteria for prob-
able CJD after presenting with rapidly progressing de-
mentia and with Rt-QuIC positivity. There were 20 pa-
tients who had a final diagnosis other than CJD. No pa-
tients met CDC criteria for possible prion disease. Five
patients did not have a final diagnosis. Of these, all
died within two years of admission (mean 182 days
until death; range 8–461; SD 203) and had paraclinical
tests suggestive of CJD.
The most common presenting symptoms for the pa-
tients with definite or probable CJD were memory loss,
decreased alertness, disorientation, executive dysfunc-
tion, myoclonus, and confusion. In the non-CJD
group, confusion, aphasia/dysphasia, memory loss,
decreased alertness, and disorientation were most fre-
quently documented. Data are presented in Table 1.
In total, 14 patients had both CSF 14-3-3 and total
Tau (normal 0–1149 pg/mL) positive for prion disease.
Otherwise, five patients had a positive 14-3-3 but nega-
tive Tau, eight were negative for both, and four patients
had inconclusive tests due to blood in the CSF sample.
Based on final diagnoses and not including those in the
undiagnosed group, our sensitivity of total Tau in CSF
was 100%, and specificity was 50%. Our sensitivity of
CSF 14-3-3 was 100%, and specificity was 37.5%.
Also, total CSF Tau was quantitatively higher in the
CJD group (6011 pg/mL, 1807–10215, SD 5945) than the
non-CJD group (2053 pg/mL, 0–7353, SD 2059), though
the differences were not statistically significant.
Total CSF protein was lower in the CJD group at an av-
erage of 12.5 mg/dL (range 8–17, SD 6.4) than in the
non-CJD group with an average of 105.0 mg/dL (14.8–
930, SD 204.1), though the difference was not statisti-
cally significant due to limited sample size.
Fourteen patients with a positive or inconclusive 14-3-
3 had reflex Rt-QuIC testing, of which one was posi-
tive. All but one patient had an MRI brain performed,
and of those, four patients had findings consistent with
sCJD, three had atypical findings consistent with vCJD
or sCJD variants, and 14 patients had findings leading
to a non-CJD diagnosis.
No patients had periodic sharp wave complexes identi-
fied on EEG, though seven were noted to have seizures
or seizure tendencies, and 15 were noted to have mod-
erate to severe background slowing consistent with en-
cephalopathy. Data are presented in Table 2.
In total, 19 patients were admitted or transferred to
the ICU, and nine of those patients were intubated.
Both patients with prion disease were intubated and
developed pneumonia contributing to respiratory fail-
ure and eventual death, as did a third patient with a
final diagnosis other than prion disease.
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Table 1. Frequency data of symptoms, including only symptoms with at least one data point reported.
Symptom Definite/Probable CJD Non-CJD(n=2) (n=20)
Memory Loss 100% 40%
Decreased Alertness 100% 30%
Disorientation 100% 25%




Personality Change 50% 10%
Apathy 50% 5%
Social Isolation 50% 0%





Bizarre Behavior 0% 15%
Tremor 0% 15%
Irritability 0% 15%
Urinary Incontinence 0% 15%
Gastrointestinal 0% 15%
Tremor 0% 15%
Pyramidal Symptoms 0% 10%
Apraxia 0% 5%
Weight Loss 0% 5%
Limb Ataxia 0% 5%
Fatigue 0% 5%
Headache 0% 5%
Handwriting Changes 0% 5%
Fasciculations 0% 5%
Table 2. Diagnostic data per group.
Definite CJD (n=1) Probable CJD (n=1) Non-CJD (n=20) Undiagnosed (n=5)
Age (years)∗ 64 70 57.4±18.3 (18–79) 64.4±6.3 (54–69)
CSF Total Tau (n) 1 pos. 1 pos. 10 pos., 10 neg. 1 pos., 4 neg.
CSF Total Tau (pg/mL)∗ 1,807 10,215 2,053.6±2,059.1 (0–7,353) 740.2 [12–1,630 ± 607.5]
CSF 14-3-3 1 pos. 1 pos. 10 pos., 6 neg., 4 inconcl. 3 pos., 2 neg.
CSF Protein (mg/dL)∗ 17 8 105±204.1 (14.8–930) 48.5±19.9 (21.6–64)
Rt-QuIC 1 pos. 13 neg. 2 neg.
EEG Findings
n 1 1 16 3
Background Slowing 1 1 10 3
Seizures 0 0 2 1
Seizure Tendencies 0 1 GPED 3 PLED 0
MRI Findings
n 1 1 19 5
Typical Findings 1 1 2 0
Atypical Findings 1 2
Normal 5 0
Other Diagnosis 11† 3
Brain Biopsy 1 pos. 1 neg.
∗ Mean±standard deviation (range).
† PRES, toxic leukoencephalopathy, psychiatric (2), CNS lymphoma, acute myeloid leukemia, NORSE/FIRE seizures, autoimmune
epilepsy, acute demyelinating encephalitis, CNS vasculitis (2), neurosyphilis (2), herpes encephalitis, dementia (3), stroke (2),
metabolic encephalopathy.
Abbreviations: GPED, generalized periodic epileptiform discharges; PLED, periodic lateralized epileptiform discharges; PRES,
posterior reversible encephalopathy syndrome; NORSE, new onset refractory status epilepticus; FIRES, febrile infection related
epilepsy syndrome; CNS, central nervous system; pos., positive; neg., negative; inconcl., inconclusive.
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Discussion
Patients with definite and probable CJD presented with
similar symptoms to those with a final diagnosis that
was not CJD, with overlap in memory loss, decreased
alertness, confusion, and aphasia or dysphasia. Only
executive dysfunction and myoclonus did not have a
high degree of overlap and were more often associated
with CJD. This made it difficult to differentiate between
conditions and identify patients for further testing. We
also identified a substantial proportion of positive tests
for CSF total Tau and 14-3-3 in patients with final diag-
noses other than CJD.
At our institution, initial testing for prion disease in-
cludes CSF t-Tau and 14-3-3. Tau is a microtubule
stabilization protein found within neurons that is el-
evated in disease processes affecting the central ner-
vous system, specifically strokes, traumatic brain in-
juries, and many forms of dementia.[5] CSF t-Tau is re-
ported to have a sensitivity of 87–90% and specificity of
67–75%.[18, 19]
Levels of the protein 14-3-3 in CSF provide an indica-
tion of neuronal injury.[5] Similarly, disease processes
such as CNS inflammation, strokes, and particularly
Alzheimer’s dementia (AD) also present with elevated
levels of 14-3-3.[5] CSF 14-3-3 is reported to have sensi-
tivity of 61–95% and specificity of 40–92%.[18, 19] Since
the incidence of Alzheimer’s dementia (AD) is much
more frequent than prion disease, the pre-test probabil-
ity of 14-3-3 in CSF is higher for AD than it is for prion
disease.[5, 20] In the present study, there was a lower
specificity of both tau and 14-3-3. Likewise, the final
diagnoses for our patients included multiple cases of
strokes and dementia.
Reasons for the false positive tests could also include
the comorbidity or severity of illnesses in our patients
as these tests were not studied extensively in critically
ill patients.[5, 19] Of the 27 patients identified, 19 were
admitted or transferred to an ICU. These patients were
critically ill, with nine of them requiring mechanical
ventilation. Standard workup for CJD, such as a thor-
ough psychiatric and neurologic examination, were dif-
ficult. In these critically ill patients, the higher fre-
quency of false positive results further complicated the
diagnostic workup.
After 2015, once available in the United States, real-
time quaking-induced conversion (Rt-QuIC) was re-
flexively tested if CSF 14-3-3 was positive. Rt-QuIC
is an assay that uses a patient’s CSF specimen to seed
reaction wells containing recombinant prion protein.
A positive test occurs when conformational change of
proteins results in amyloid formation. Rt-QuIC is de-
scribed as an optimal method of prion protein detection
without requiring brain biopsy.[5] The reported sensi-
tivity for the majority of sCJD subtypes is 91–100%, and
it has a specificity of 98.5–100%.[5, 21, 22] Therefore,
testing with Rt-QuIC would be of benefit even in the
absence of positive 14-3-3, especially in patient popu-
lations that could have a higher pre-test probability of
non-CJD diagnoses.
With every sample, CSF protein was also analyzed. In
the present study, CSF protein was higher in patients
with a non-CJD final diagnosis. Direct neuronal injury
or disruption of the blood-brain barrier causing protein
release is not associated with prion disease.[5] While
the differences in CSF protein were not statistically sig-
nificant for our limited sample size, there may be a neg-
ative correlation. Further study could be directed to-
wards this negative correlation.
Of the five patients in our sample who did not have a
final diagnosis, only two had Rt-QuIC testing, which
was negative, and two patients had a positive 14-3-3
and MRI findings consistent with vCJD. All five died
within two years of presentation. While rare, variant
CJD in these patients is possible, especially since the
utility of Rt-QuIC in the diagnosis of vCJD is limited. In
situations like these, where the workup is ambiguous
and no other causative illness is found, or in the case of
critically ill patients, non-standard laboratory tests may
be of benefit. The nonspecific CSF biomarkers currently
being investigated for the diagnosis of prion disease in-
clude Tau subtype ratios, neuron-specific enolase, S100
beta, and alpha-synuclein. While their sensitivities and
specificities vary, and they are not included in current
diagnostic algorithms, their utility lies in otherwise am-
biguous workups.[5, 18]
Of all patients in our sample tested for prion dis-
ease, nine (33%) required intubation for respiratory
infections. A recent review confirmed that endotra-
cheal intubation and extubation are aerosol-generating
procedures.[23] Since it has been demonstrated in a
mouse model that prion protein can be spread through
aerosols, it is important that proper personal protective
equipment be employed for any aerosol-generating
procedure performed on patients with prion dis-
ease.[10] As testing is often ambiguous, aerosol precau-
tions should be taken with any patient in whom there
is suspicion of prion disease.
Conclusions
The presenting symptoms in patients with prion dis-
ease largely overlap with patients whose final diag-
nosis is not prion disease. There is a high false posi-
tive frequency of both CSF total Tau and CSF 14-3-3,
especially in critically ill patients. The systematic in-
corporation of Rt-QuIC may increase diagnostic accu-
racy. The diagnosis of prion disease demands the in-
corporation of signs and symptoms, diagnostic tests,
and imaging. A high level of suspicion is necessary so
that the disease is not missed in critically ill patients,
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and aerosol precautions should be employed when per-
forming any aerosol-generating procedure for patients
in whom there is any suspicion of prion disease.
Limitations
The statistical analysis was limited due to our small
sample size. After 2016, our laboratory reported CSF
total-Tau to a maximum of >4000, whereas previously
there was no upper limit.
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